Clinical Trials for Pancreas Cancer

Investigator-Initiated Feasibility Study of a Novel Endoscopic Ultrasound Guided Microwave Ablation Device in Patients With Locally Advanced, Unresectable, or Metastatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with stage III–IV locally advanced unresectable or metastatic cancer and a tumor ≥1 cm accessible by endoscopic ultrasound through the gastric wall, such as a pancreatic or hepatic lesion, receive investigational endoscopic ultrasound-guided microwave ablation. This single-arm study primarily assesses whether the device can safely deliver tumor-destroying microwave energy.

ClinicalTrials.gov ID: NCT07817147

A Pilot Study of Spatially Fractionated Radiation Therapy in Patients with Extra-Cranial Soft Tissue Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors and at least two extracranial soft tissue metastases (one ≥4 cm) requiring palliative radiation, comparing lattice radiation therapy (LRT)—a spatially fractionated radiotherapy technique that may enhance immune effects—to standard SBRT, with each patient receiving both treatments at different sites.

ClinicalTrials.gov ID: NCT05837767

A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with ECOG 0–1 and selected unresectable or metastatic solid tumors without a standard treatment option receive oral APL-5125, an investigational CK2α inhibitor. The expansion cohort focuses on colorectal cancer after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and anti-VEGF therapy, plus anti-EGFR therapy for RAS-wild-type disease.

ClinicalTrials.gov ID: NCT06399757

Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring KRAS G12C mutations (including pretreated NSCLC and other solid tumors), who receive a combination of the investigational KRAS G12C inhibitors RMC-6291 and RMC-6236. Both agents specifically inhibit KRAS G12C mutant protein to suppress tumor growth, and eligibility includes both KRAS G12C inhibitor–naïve and previously treated patients, excluding those with primary CNS tumors or active brain metastases.

ClinicalTrials.gov ID: NCT06128551

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring deleterious germline or somatic DNA damage response (DDR) gene aberrations who have progressed after standard therapy, including those with prior platinum or PARP inhibitor exposure. Patients receive oral talazoparib, a PARP1/2 inhibitor that exploits defective DNA repair in cancer cells, administered daily in 28-day cycles until disease progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT04550494

Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adults with advanced solid tumors—including RAS-mutated colorectal, pancreatic, other RAS-mutant tumors, EGFR-altered or RAS-mutant glioblastoma, and ocular melanoma (with GNAQ or GNA11 mutations)—this study tests oral neratinib (an irreversible pan-HER tyrosine kinase inhibitor) combined with divalproex sodium (a histone deacetylase inhibitor) in patients who have progressed on standard therapies.

ClinicalTrials.gov ID: NCT03919292

Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced, metastatic, or recurrent mesothelioma (epithelioid or biphasic with >80% epithelioid), or other solid tumors with high mesothelin expression (≥50% of tumor cells), who have progressed after standard therapies. Treatment involves lymphodepleting chemotherapy followed by a single infusion of autologous CAR T cells (TNhYP218) engineered to target a membrane-proximal epitope of mesothelin, using naive/stem cell memory T cells to potentially enhance efficacy.

ClinicalTrials.gov ID: NCT06885697

A Phase 2 Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with untreated, biopsy-proven metastatic pancreatic adenocarcinoma (ECOG 0–1) receive first-line gemcitabine plus nab-paclitaxel combined with the TheraBionic device, which delivers low-intensity, amplitude‑modulated radiofrequency electromagnetic fields intended to modulate tumor cell signaling and calcium channel activity. Key exclusions include prior systemic therapy for metastatic disease, recent adjuvant/neoadjuvant gemcitabine or nab-paclitaxel, brain metastases, significant cardiopulmonary disease, and concurrent use of L-/T-type calcium channel blockers unless discontinued.

ClinicalTrials.gov ID: NCT05776524

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma after at least one prior systemic therapy undergo [68Ga]Ga DOTA-5G PET/CT selection, then receive [177Lu]Lu DOTA-ABM-5G radioligand therapy. The investigational theranostic pair targets DOTA-5G–avid lesions to confirm uptake for enrollment and deliver lutetium-177 beta radiation to tumors.

ClinicalTrials.gov ID: NCT04665947

A Phase 1b Study of Gemcitabine and Leflunomide in Patients With Unresectable Pancreatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable advanced pancreatic ductal adenocarcinoma (ECOG 0–1) planned for single-agent gemcitabine receive gemcitabine plus oral leflunomide, an immunomodulatory antiproliferative agent whose active metabolite inhibits dihydroorotate dehydrogenase (pyrimidine synthesis) and may inhibit tyrosine kinases. The study evaluates safety, DLTs, and preliminary efficacy of this combination, with key exclusions for recent systemic therapy, infection, and significant drug–drug interactions.

ClinicalTrials.gov ID: NCT06454383